For AbbVie Inc. [ABBV], Analyst sees a rise to $135. What next?

AbbVie Inc. [NYSE: ABBV] closed the trading session at $110.80 on 04/21/21. The day’s price range saw the stock hit a low of $109.35, while the highest price level was $111.44. The company report on April 7, 2021 that AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

– Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which SKYRIZI demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo[1].

– In the pivotal studies, patients treated with SKYRIZI received four maintenance doses a year, following two initiation doses[1].

The stocks have a year to date performance of 3.41 percent and weekly performance of 4.63 percent. The stock has been moved at 31.42 percent over the last six months. The stock has performed 4.63 percent around the most recent 30 days and changed -1.62 percent over the most recent 3-months.

If compared to the average trading volume of 7.27M shares, ABBV reached to a volume of 6173658 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about AbbVie Inc. [ABBV]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABBV shares is $122.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABBV stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

RBC Capital Mkts have made an estimate for AbbVie Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 07, 2021. While these analysts kept the previous recommendation, Bernstein raised their target price to Outperform. The new note on the price target was released on November 10, 2020, representing the official price target for AbbVie Inc. stock. Previously, the target price had yet another raise to $98, while Berenberg analysts kept a Hold rating on ABBV stock.

The Average True Range (ATR) for AbbVie Inc. is set at 1.99, with the Price to Sales ratio for ABBV stock in the period of the last 12 months amounting to 4.23. The Price to Book ratio for the last quarter was 14.99, with the Price to Cash per share for the same quarter was set at 4.85. Price to Free Cash Flow for ABBV in the course of the last twelve months was 21.35 with Quick ratio for the last quarter at 0.70.

ABBV stock trade performance evaluation

AbbVie Inc. [ABBV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.63. With this latest performance, ABBV shares gained by 4.63% in over the last four-week period, additionally plugging by 31.42% over the last 6 months – not to mention a rise of 37.88% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABBV stock in for the last two-week period is set at 62.37, with the RSI for the last a single of trading hit 68.54, and the three-weeks RSI is set at 58.89 for AbbVie Inc. [ABBV]. The present Moving Average for the last 50 days of trading for this stock 106.64, while it was recorded at 108.65 for the last single week of trading, and 99.54 for the last 200 days.

AbbVie Inc. [ABBV]: An insightful look at the core fundamentals

Operating Margin for any stock indicates how profitable investing would be, and AbbVie Inc. [ABBV] shares currently have an operating margin of +34.12 and a Gross Margin at +69.18. AbbVie Inc.’s Net Margin is presently recorded at +9.95.

Return on Total Capital for ABBV is now 19.65, given the latest momentum, and Return on Invested Capital for the company is 6.22. Return on Equity for this stock inclined to 185.81, with Return on Assets sitting at 3.80. When it comes to the capital structure of this company, AbbVie Inc. [ABBV] has a Total Debt to Total Equity ratio set at 665.82. Additionally, ABBV Total Debt to Total Capital is recorded at 86.94, with Total Debt to Total Assets ending up at 57.82. Long-Term Debt to Equity for the company is recorded at 599.46, with the Long-Term Debt to Total Capital now at 78.28.

Reflecting on the efficiency of the workforce at the company, AbbVie Inc. [ABBV] managed to generate an average of $96,936 per employee. Receivables Turnover for the company is 6.43 with a Total Asset Turnover recorded at a value of 0.38.AbbVie Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.80.

Earnings per share (EPS) analysis for AbbVie Inc. [ABBV] stock

With the latest financial reports released by the company, AbbVie Inc. posted 2.42/share EPS, while the average EPS was predicted by analysts to be reported at 2.25/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABBV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbbVie Inc. go to 4.03%.

AbbVie Inc. [ABBV]: Insider Ownership positions

There are presently around $132,748 million, or 69.70% of ABBV stock, in the hands of institutional investors. The top three institutional holders of ABBV stocks are: VANGUARD GROUP INC with ownership of 142,563,074, which is approximately -1.228% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 124,423,484 shares of the stock with an approximate value of $13.79 billion in ABBV stocks shares; and STATE STREET CORP, currently with $8.66 billion in ABBV stock with ownership of nearly -0.059% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in AbbVie Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,436 institutional holders increased their position in AbbVie Inc. [NYSE:ABBV] by around 59,810,309 shares. Additionally, 969 investors decreased positions by around 75,196,895 shares, while 272 investors held positions by with 1,063,081,958 shares. The mentioned changes placed institutional holdings at 1,198,089,162 shares, according to the latest SEC report filing. ABBV stock had 284 new institutional investments in for a total of 11,115,753 shares, while 90 institutional investors sold positions of 2,325,095 shares during the same period.

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on skype
Skype
Share on reddit
Reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam